News & Announcements
-
Orphan Drug Status to GaM and Total Voting Rights
/**/ RNS Number : 0526P IQ-AI Limited 09 October 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating ATRT Total Voting Rights Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces the U.S. Food
-
Holding(s) in Company
/**/ RNS Number : 5384O IQ-AI Limited 03 October 2023 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to
-
IQ-AI shares cease trading on the OTCQB
/**/ RNS Number : 9599M IQ-AI Limited 19 September 2023 19 September 2023 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI shares cease trading on the OTCQB Venture Market in the United States Further to the announcement of 1 September 2021, IQ-AI Limited (LSE: IQAI) has decided to cease trading on the OTCQB
-
Reduced Gadolinium Approach Validated
/**/ RNS Number : 7871L IQ-AI Limited 08 September 2023 8 September 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce the results of a study
-
Update on Collaboration Agreement with Mayo Clinic
/**/ RNS Number : 8096J IQ-AI Limited 18 August 2023 18 August 2023 IQ-AI Ltd (“IQ-AI” or the “Company“) Update on Collaboration Agreement with Mayo Clinic Further to the RNS dated 8 February 2022, IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF) announces that the collaboration agreement signed with the Mayo Clinic for the development